Valion Bio, Inc. (VBIO) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) is a late-stage biopharmaceutical company focused on its lead TLR5 agonist program, Entolimod, for Acute Radiation Syndrome (ARS) and oncology indications. In December 2025, the company vertically integrated by acquiring assets from Scorpius Holdings to form Velocity Bioworks, Inc. (VBI), a Contract Development and Manufacturing Organization (CDMO). The company operates two segments: Biopharma and CDMO. In April 2026, the company officially changed its name and ticker symbol to Valion Bio, Inc. (VBIO).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 (Continuing Operations) | $0 (Continuing Operations) |
| Net Loss | $(6.20) million | $(1.50) million |
| Operating Expenses | $5.63 million | $1.38 million |
| Cash and Cash Equivalents | $7.22 million | $0.67 million |
| Working Capital | $5.31 million | $12.36 million |
| Convertible Note Payable (Net) | $6.90 million | $0 |
| Accumulated Deficit | $(59.03) million | $(45.04) million |
Note: Discontinued operations (ClearUP business) generated $24,000 in revenue and $23,000 in net income for Q1 2026.
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased by $4.26 million (309%) year-over-year. This is primarily due to the integration of the CDMO segment (Velocity Bioworks), which added approximately $2.7 million in operating costs, alongside increased headcount and professional fees.
- Debt Financing: In December 2025, the company issued a senior secured convertible note of $16.25 million to fund the CDMO acquisition. This resulted in $0.65 million of interest expense in Q1 2026, compared to zero in Q1 2025.
- Inventory Recognition: The company capitalized $0.75 million of inventory related to the validation of Entolimod materials for distribution, a non-cash asset increase not present in the prior year.
- Lease Obligations: New facility leases for the CDMO operations in San Antonio resulted in $10.3 million in Right-of-Use assets and corresponding lease liabilities recorded in Q1 2026.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. With a cash burn rate of approximately $5.0 million in Q1 2026 and cash reserves of $7.2 million, the company expects to require additional financing to fund operations and clinical trials.
- Nasdaq Compliance: The company received notice on March 19, 2026, of non-compliance with Nasdaq's minimum bid price requirement (stock price below $1.00 for 30 consecutive days). The company has until September 15, 2026, to regain compliance or risk delisting.
- Liquidity Strategy: On February 6, 2026, the company entered into a Common Stock Purchase Agreement (Equity Line of Credit) with Tumim Stone Capital, LLC, allowing for the sale of up to $50 million of common stock. A commitment fee of $0.375 million was paid via pre-funded warrants.
- Operational Milestones: The company validated Entolimod inventory for distribution and demonstrated a 200-fold manufacturing scale-up. It is actively engaging with federal agencies (BARDA, FDA) regarding potential Strategic National Stockpile purchases.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.2 million cash balance against the current burn rate of ~$5 million/quarter and the timeline for closing the Tumim equity line.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 threshold for 10 consecutive days before the September 15, 2026 deadline to avoid delisting.
- Debt Covenants: Review the terms of the $16.25 million convertible note, specifically the conversion price ($2.2310), the floor price ($0.39), and potential dilution upon conversion.
- CDMO Revenue: Assess the timeline for Velocity Bioworks to generate external revenue, as the company currently expects no significant CDMO revenue in the near term.
- Preferred Stock: Note the existence of Series B and Series C preferred stock classified as temporary equity, which may have liquidation preferences ahead of common stockholders.